whats the best crypto Knowledge

Li Bin: Fang Hongbo, chairman of Midea, will be the chief experience officer of Weilai ET9 and will test drive together. Li Bin, founder, chairman and CEO of Weilai, announced that Weibo said that Fang Hongbo, chairman of Midea, will be the chief experience officer of Weilai ET9 and test drive this upcoming administrative flagship together. Li Bin said that he asked Fang Hongbo three questions, and Fang Hongbo's answer about market competition was very good: "Actively participate in involution, compare cost and efficiency, and at the same time bravely jump out of involution, don't roll on the floor, and pierce the ceiling." (Sina Technology)Lan Foan met with World Trade Organization Director-General Ivira. On December 9, 2024, Minister Lan Foan met with World Trade Organization Director-General Ivira in Beijing. The two sides exchanged views on enhancing the transparency of subsidy policy, supporting the operation of global trust funds and maintaining the multilateral trading system.The opposition party in South Korea said that Yin Xiyue was insane. On the morning of December 12, local time, South Korean President Yin Xiyue made another televised speech, refused to step down early, and denied that martial law was a crime of civil strife. After Yin Xiyue's speech, public opinion in South Korea immediately criticized him. South Korea's largest opposition party, the Common Democratic Party, said that Yin Xiyue was mentally ill and called on the South Korean National Assembly to pass the impeachment case. After Yin Xiyue's speech, Han Dongxun, the representative of the ruling party in South Korea, also said that Yin Xiyue's speech had no introspection and was rationalizing his behavior. Some commentators pointed out that Yin Xiyue may have expected that he could not prevent the National Assembly from passing the impeachment case and was trying to influence the final ruling of the Constitutional Court. I am afraid that the chaos in Korean politics will continue.

A former employee of Adebio was sentenced and involved in AstraZeneca employees' insurance fraud case. A former employee of the genetic testing company Aidebio, which worked closely with AstraZeneca, committed medical insurance fraud together with AstraZeneca sales staff during his tenure in the company. He was sentenced to three years' imprisonment and fined for fraud, and I pleaded guilty. A judgment obtained shows that Ma, a former employee of Aide Bio involved in the case, conspired with AstraZeneca employees to tamper with the genetic test report during his tenure. He began to accept public security investigation in September 2021 and was sentenced in August 2023. However, on December 9, 2024, the company replied that "there is no problem (cooperation with AstraZeneca), which has no impact on us and has nothing to do with us" and denied that any employees were involved. (financial magazine)India's NIFTY 50 index fell, with the latest drop of 0.1%.A former employee of Adebio was sentenced and involved in AstraZeneca employees' insurance fraud case. A former employee of the genetic testing company Aidebio, which worked closely with AstraZeneca, committed medical insurance fraud together with AstraZeneca sales staff during his tenure in the company. He was sentenced to three years' imprisonment and fined for fraud, and I pleaded guilty. A judgment obtained shows that Ma, a former employee of Aide Bio involved in the case, conspired with AstraZeneca employees to tamper with the genetic test report during his tenure. He began to accept public security investigation in September 2021 and was sentenced in August 2023. However, on December 9, 2024, the company replied that "there is no problem (cooperation with AstraZeneca), which has no impact on us and has nothing to do with us" and denied that any employees were involved. (financial magazine)

Yamato: Raising the target price of IWC to HK$ 20 has a more positive view on next year's revenue growth. Yamato published a report that under the strong demand from Malaysia, the bank has a more positive view on IWC's revenue growth next year. In addition, the bank believes that the external financing of operating GDSI, a data center outside the mainland, will release shareholder value. However, as GDSI will be separated from IWC's consolidated statements in the fourth quarter of this year, the bank believes that IWC's short-term re-evaluation will still mainly depend on its mainland business performance, so it still maintains a wait-and-see attitude. The bank maintained its "hold" rating on IWC, and its target price was raised from HK$ 8.6 to HK$ 20. Considering the increase in capital expenditure of IWC from 2025 to 2026, the bank raised its revenue forecast for this year and next by 5% to 24%, mainly due to the strong demand in the international market driven by short video platforms. In addition, in view of the fact that the company raised its capital expenditure guideline from 6.5 billion yuan to 11 billion yuan this year, the bank raised its capital expenditure forecast from 6.7 billion yuan to 11 billion yuan in 2024 and from 3.5 billion yuan to 10.5 billion yuan in 2025. In addition, the bank will raise the adjusted EBITDA forecast of IWC this year and next by 4% to 13% to consider the EBITDA contribution of its overseas business; It is estimated that the total revenue will increase by 15% this year (10% compared with the previous forecast) and 33% next year (15% compared with the previous forecast). The adjusted EBITDA is expected to increase by 11% and 25% this year and next (8% and 15% compared with the previous forecast).A former employee of Adebio was sentenced and involved in AstraZeneca employees' insurance fraud case. A former employee of the genetic testing company Aidebio, which worked closely with AstraZeneca, committed medical insurance fraud together with AstraZeneca sales staff during his tenure in the company. He was sentenced to three years' imprisonment and fined for fraud, and I pleaded guilty. A judgment obtained shows that Ma, a former employee of Aide Bio involved in the case, conspired with AstraZeneca employees to tamper with the genetic test report during his tenure. He began to accept public security investigation in September 2021 and was sentenced in August 2023. However, on December 9, 2024, the company replied that "there is no problem (cooperation with AstraZeneca), which has no impact on us and has nothing to do with us" and denied that any employees were involved. (financial magazine)Yamato: Raising the target price of IWC to HK$ 20 has a more positive view on next year's revenue growth. Yamato published a report that under the strong demand from Malaysia, the bank has a more positive view on IWC's revenue growth next year. In addition, the bank believes that the external financing of operating GDSI, a data center outside the mainland, will release shareholder value. However, as GDSI will be separated from IWC's consolidated statements in the fourth quarter of this year, the bank believes that IWC's short-term re-evaluation will still mainly depend on its mainland business performance, so it still maintains a wait-and-see attitude. The bank maintained its "hold" rating on IWC, and its target price was raised from HK$ 8.6 to HK$ 20. Considering the increase in capital expenditure of IWC from 2025 to 2026, the bank raised its revenue forecast for this year and next by 5% to 24%, mainly due to the strong demand in the international market driven by short video platforms. In addition, in view of the fact that the company raised its capital expenditure guideline from 6.5 billion yuan to 11 billion yuan this year, the bank raised its capital expenditure forecast from 6.7 billion yuan to 11 billion yuan in 2024 and from 3.5 billion yuan to 10.5 billion yuan in 2025. In addition, the bank will raise the adjusted EBITDA forecast of IWC this year and next by 4% to 13% to consider the EBITDA contribution of its overseas business; It is estimated that the total revenue will increase by 15% this year (10% compared with the previous forecast) and 33% next year (15% compared with the previous forecast). The adjusted EBITDA is expected to increase by 11% and 25% this year and next (8% and 15% compared with the previous forecast).